OptimizeRx (OTCMKTS:OPRX) had its target price lifted by Lake Street Capital to $2.50 in a research report released on Wednesday morning, The Fly reports. They currently have a buy rating on the technology company’s stock.

Shares of OptimizeRx (OTCMKTS:OPRX) opened at $1.55 on Wednesday. OptimizeRx has a 1 year low of $0.63 and a 1 year high of $1.66. The stock has a market cap of $45.38, a price-to-earnings ratio of -22.14 and a beta of 0.77.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/optimizerx-oprx-pt-raised-to-2-50-at-lake-street-capital/1906049.html.

OptimizeRx Company Profile

OptimizeRx Corporation is a technology solutions company. The Company focuses on the healthcare industry. The Company connects patients, physicians and pharmaceutical manufacturers through technology. The Company’s solutions provide pharmaceutical manufacturers a direct to physician channel for communicating and promoting products.

The Fly

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.